Compare Cipla with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SHASUN PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SHASUN PHARMA CIPLA/
SHASUN PHARMA
 
P/E (TTM) x 24.1 123.9 19.5% View Chart
P/BV x 2.5 8.5 28.9% View Chart
Dividend Yield % 0.7 0.2 279.7%  

Financials

 CIPLA   SHASUN PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-19
SHASUN PHARMA
Mar-14
CIPLA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs67894 719.7%   
Low Rs48446 1,061.0%   
Sales per share (Unadj.) Rs198.2214.2 92.6%  
Earnings per share (Unadj.) Rs18.55.3 347.1%  
Cash flow per share (Unadj.) Rs35.015.8 221.1%  
Dividends per share (Unadj.) Rs3.001.00 300.0%  
Dividend yield (eoy) %0.51.4 36.1%  
Book value per share (Unadj.) Rs186.353.3 349.3%  
Shares outstanding (eoy) m805.7056.62 1,423.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.90.3 897.9%   
Avg P/E ratio x31.413.1 239.4%  
P/CF ratio (eoy) x16.64.4 375.8%  
Price / Book Value ratio x3.11.3 237.9%  
Dividend payout %16.218.7 86.4%   
Avg Mkt Cap Rs m468,0313,958 11,825.7%   
No. of employees `00022.6NA-   
Total wages/salary Rs m28,5652,164 1,320.3%   
Avg. sales/employee Rs Th7,053.1NM-  
Avg. wages/employee Rs Th1,261.5NM-  
Avg. net profit/employee Rs Th659.1NM-  
INCOME DATA
Net Sales Rs m159,71012,127 1,317.0%  
Other income Rs m4,766229 2,077.9%   
Total revenues Rs m164,47512,356 1,331.1%   
Gross profit Rs m30,9731,009 3,069.5%  
Depreciation Rs m13,263594 2,234.3%   
Interest Rs m1,684415 405.8%   
Profit before tax Rs m20,791230 9,051.5%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,695-73 -7,831.8%   
Profit after tax Rs m14,924302 4,939.9%  
Gross profit margin %19.48.3 233.1%  
Effective tax rate %27.4-31.7 -86.5%   
Net profit margin %9.32.5 375.1%  
BALANCE SHEET DATA
Current assets Rs m124,2666,884 1,805.0%   
Current liabilities Rs m37,7158,456 446.0%   
Net working cap to sales %54.2-13.0 -418.2%  
Current ratio x3.30.8 404.7%  
Inventory Days Days9162 147.0%  
Debtors Days Days95108 88.2%  
Net fixed assets Rs m105,1904,970 2,116.4%   
Share capital Rs m1,611113 1,422.2%   
"Free" reserves Rs m148,5112,875 5,165.8%   
Net worth Rs m150,1233,020 4,970.6%   
Long term debt Rs m38,3011,817 2,107.4%   
Total assets Rs m239,63313,347 1,795.4%  
Interest coverage x13.31.6 859.1%   
Debt to equity ratio x0.30.6 42.4%  
Sales to assets ratio x0.70.9 73.4%   
Return on assets %6.95.4 129.0%  
Return on equity %9.910.0 99.4%  
Return on capital %11.813.3 88.8%  
Exports to sales %34.746.4 74.9%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs m55,4195,622 985.8%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m57,4105,843 982.6%   
Fx outflow Rs m19,0412,173 876.2%   
Net fx Rs m38,3683,669 1,045.6%   
CASH FLOW
From Operations Rs m16,911398 4,253.4%  
From Investments Rs m-16,687-1,635 1,020.6%  
From Financial Activity Rs m-3,4871,309 -266.5%  
Net Cashflow Rs m-3,45171 -4,847.1%  

Share Holding

Indian Promoters % 16.0 39.2 40.8%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 3.6 338.9%  
FIIs % 23.7 17.6 134.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 39.6 66.2%  
Shareholders   161,166 20,750 776.7%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   FULFORD INDIA  VENUS REMEDIES  PIRAMAL ENTERPRISES  WOCKHARDT  AUROBINDO PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms Over 1,900 Points after Government Slashes Corporate Tax Rates(12:30 pm)

Share markets in India jumped sharply after FM Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 20, 2019 02:59 PM

TRACK CIPLA

CIPLA - DIVIS LABORATORIES COMPARISON

COMPARE CIPLA WITH

MARKET STATS